UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 30549




                                   FORM 10-QSB




(MarkOne)

[X]  QUARTERLY  REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES  EXCHANGE ACT
     OF 1934
                               For the quarterly period ended September 30, 2002

[  ] TRANSACTION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT
                        For the transition period from            to
                                                       ----------    -----------

                                                 Commission file number: 0-27489
                                                                         -------

                                 DuraVest, Inc.
        -----------------------------------------------------------------
        (Exact name of small business issuer as specified in its charter)

            Florida                                              59-2624574
-------------------------------                              -------------------
(State or Other Jurisdiction of                              (IRS Employer
Incorporation or Organization)                               Identification No.)

      37 Prince Arthur Avenue, Suite 300, Toronto, Ontario, Canada M5R 1E2
      --------------------------------------------------------------------
                    (Address of principal executive offices)


                                 (416) 961-1409
                           ---------------------------
                           (Issuer's telephone number)



        ---------------------------------------------------------------
               (Former name, former address and former fiscal year
                         (if changed since last report)




                APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
                   PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Check whether the  registrant  filed all  documents  and reports  required to be
filed by Section 12, 13 or 15(d) of the Exchange Act after the  distribution  of
securities under a plan confirmed by a Court. Yes [ ] No [ ]




                      APPLICABLE ONLY TO CORPORATE ISSUERS

The  number of shares  outstanding  of each of the  issuer's  classes  of common
equity, as of November 5, 2002 was 36,766,640 shares of common stock.

Transitional Small Business Disclosure Format (Check one):  Yes [X]  No [  ]

<PAGE>

                                      INDEX

                                                                           Page
                                                                          Number
                                                                          ------

Part I.  Financial Information


     Item 1.  Financial Statements

              Condensed Balance Sheet as of September 30, 2002               3

              Condensed Statements of Loss for Nine Months
              Ended September 30, 2002 and September 30, 2001,
              the Nine Months ended September 30, 2002 and
              September 30, 2001 and since Inception                         4

              Condensed Statements of Cash Flows for Nine
              Months Ended September 30, 2002
              And September 30, 2001 and Since Inception                     5

              Summary of Significant Accounting Policies                     6

              Notes to Condensed Financial Statements                        8

     Item 2.  Plan of Operation                                             12


Part II. Other Information

     Item 1.  Legal Proceedings                                             15

     Item 2.  Changes in Securities                                         15

     Item 3.  Defaults in Senior Securities                                 15

     Item 4.  Submission of Matters to a Vote of Securities Holders         15

     Item 5.  Other Information                                             15

     Item 6.  Exhibits and Reports on Form 8-K                              15

Signatures                                                                  16

Certifications                                                              17



                                       2
<PAGE>

                         PART I - FINANCIAL INFORMATION


Item 1.  Financial Statements
-----------------------------


                                 DURAVEST, INC.

                             CONDENSED BALANCE SHEET




September 30,                                                           2002
-------------                                                         ---------


Assets
   Cash                                                               $   6,577
                                                                      ---------

                                                                      $   6,577
                                                                      =========

Liabilities and Stockholders' Equity

Total liabilities                                                     $     800

Commitments and Contingencies

Stockholders' Equity

Preferred stock, $0.001 par value, 20,000,000
  shares authorized, 0 shares issued and outstanding
Common stock, $0.001 par value; 80,000,000 shares
  authorized; 36,766,640 shares issued and outstanding                    3,680
Additional paid-in capital                                              448,820
Deficit accumulated during the development stage                       (446,723)
                                                                      ---------
Total stockholders' equity                                                5,777
                                                                      ---------

                                                                      $   6,577
                                                                      =========




                                       3
<PAGE>
<TABLE>
<CAPTION>


                                                            DURAVEST, INC.

                                                  CONDENSED STATEMENTS OF OPERATIONS


                                                         For the three   For the three    For the nine    For the nine     From
                                                         months ended    months ended     months ended    months ended    inception
                                                           Sep. 30,        Sep. 30,         Sep. 30,        Sep. 30,     to Sep. 30,
                                                             2002            2001             2002            2001          2002
                                                         -------------   -------------    -------------   ------------  ------------
<S>                                                      <C>              <C>             <C>            <C>             <C>
Development stage expenses:
     Selling, general and administrative, excluding
       non-cash compensation (benefit) expense            $    5,979      $    4,931      $   27,844      $   43,212      $ 445,905
                                                          ----------      ----------      ----------      ----------      ---------

Total development stage expenses                               5,979           4,931          27,844          43,212        445,905
                                                          ----------      ----------      ----------      ----------      ---------

Loss from operations                                          (5,979)         (4,931)        (27,844)        (43,212)      (445,905)

Other expense:
     Foreign currency translation loss                           162             199             158             202            818
                                                          ----------      ----------      ----------      ----------      ---------

Net loss                                                      (6,142)         (5,130)        (28,002)        (43,414)      (446,723)
                                                          ----------      ----------      ----------      ----------      ---------

Net loss applicable to common stock                       $   (6,142)     $   (5,130)     $  (28,002)     $  (43,414)     $(446,723)
                                                          ==========      ==========      ==========      ==========      =========

Net loss per common share (basic and diluted)                  (0.01)     $    (0.01)     $    (0.01)     $    (0.01)
                                                          ==========      ==========      ==========      ==========

Weighted average number of common shares outstanding      36,766,640      36,766,640      36,766,640      36,766,640
                                                          ==========      ==========      ==========      ==========
</TABLE>


                                                                   4
<PAGE>
<TABLE>
<CAPTION>


                                         DURAVEST, INC.

                                CONDENSED STATEMENTS OF CASH FLOWS


                                                        For the nine      For the nine
                                                        months ended      months ended       From
                                                          Sep. 30,          Sep. 30,      inception to
                                                            2002              2001        Sep. 30, 2002
                                                        ------------      -------------   -------------
<S>                                                      <C>               <C>              <C>
Operating activities:
   Net loss                                              $ (28,002)        $ (43,414)       $(446,723)

   Adjustments to reconcile net loss to net cash
     used in operating activities:
   Change in assets and liabilities:
         Accounts payable                                   (5,966)                               800
                                                         ---------         ----------       ---------

Net cash used in operating activities                      (33,968)          (43,414)        (445,923)
                                                         ---------         ----------       ---------
Financing activities:
   Proceeds from issuance of common stock                        -                 -          452,500
                                                         ---------         ----------       ---------

Net cash provided by financing activities                        -                 -          452,500
                                                         ---------         ----------       ---------

Net increase (decrease) in cash and cash equivalents       (33,968)          (43,414)           6,577
                                                         ---------         ----------       ---------

Cash and equivalents, beginning of year                     40,545             98,571               -
                                                         ---------         ----------       ---------

Cash and equivalents, September 30, 2002                 $   6,577         $   55,157       $   6,577
                                                         =========         ==========       =========

</TABLE>



                                                    5
<PAGE>


                                 DURAVEST, INC.

                   SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES


BASIS OF PRESENTATION
---------------------

The accompanying  unaudited condensed financial statements have been prepared in
accordance with generally accepted  accounting  principles for interim financial
information  and with Article 310 of Regulation  S-B.  Accordingly,  they do not
include all of the  information  and  footnotes  required by generally  accepted
accounting principles for complete financial statements.  All adjustments which,
in the opinion of management,  are considered  necessary for a fair presentation
of the results of  operations  for the periods  shown are of a normal  recurring
nature and have been reflected in the unaudited condensed financial  statements.
The  results  of  operations  for the  periods  presented  are  not  necessarily
indicative  of the results  expected  for the full fiscal year or for any future
period.  The  information   included  in  these  unaudited  condensed  financial
statements  should be read in conjunction  with Plan of Operation and Results of
Operations   contained  in  this  report  and  the  financial   statements   and
accompanying notes included in the Duravest,  Inc. (the "Company") Annual Report
on Form 10-K for the fiscal year ended December 31, 2001.


NATURE OF OPERATIONS
--------------------

DuraVest, Inc. (the "Company") was incorporated on August 1, 1980 under the laws
of the State of Florida as Ronnie  Interior  Designs,  Inc.  for the  purpose of
merging with or acquiring another company.

On October 14, 1997,  Ronnie Interior  Designs,  Inc. changed its name to Ronnie
Systems, Inc.

On  March  13,  1998,   the  Company   amended  and  restated  its  articles  of
incorporation and changed its name to Great Wall Food and Beverage Corporation.

On  November  9,  2001,  the  Company  amended  and  restated  its  articles  of
incorporation and changed its name to Duravest, Inc.

The Company has been  operating  as a  development  stage  enterprise  since its
inception  and  is  devoting  substantially  all  its  efforts  to  the  ongoing
development of the Company.


CASH AND CASH  EQUIVALENTS
--------------------------

The Company  considers  all highly liquid  investments  with a maturity of three
months or less when purchased to be cash equivalents.




                                       6
<PAGE>

                                 DURAVEST, INC.

                   SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES


FAIR VALUE OF FINANCIAL INSTRUMENTS
-----------------------------------

The carrying amounts of the Company's financial assets,  including cash and cash
equivalents approximate fair value because of their short maturities.


USE OF ESTIMATES
----------------

The preparation of financial statements in conformity with accounting principles
generally  accepted in the United States of America requires  management to make
estimates  and  assumptions  that  affect  the  reported  amounts  of assets and
liabilities  and disclosure of contingent  assets and liabilities at the date of
the  financial  statements  and the  reported  amounts of revenues  and expenses
during the reporting period. Actual results could differ from those estimates.


ADVERTISING
-----------

The Company  conducts  nondirect  response  advertising for the promotion of its
products.  These  costs are  expensed  as  incurred.  Advertising  costs for the
periods ended September 30, 2002 and 2001 were $910 and $0 respectively.


INCOME TAXES
------------

The Company accounts for income taxes pursuant to the provisions of Statement of
Financial  Accounting  Standards (SFAS) No. 109,  "Accounting for Income Taxes,"
which requires, among other things, a liability approach to calculating deferred
income  taxes.  The asset and liability  approach  requires the  recognition  of
deferred tax liabilities and assets for the expected future tax  consequences of
temporary  differences  between the carrying amounts and the tax bases of assets
and liabilities.


FOREIGN CURRENCY TRANSLATION
----------------------------

During 1999 the Company opened a bank account  denominated in a foreign currency
which  is used  to pay for  some  operational  expenses.  The  bank  account  is
translated using rates of exchange at September 30, 2002 and 2001;  expenses are
translated at weighted  average  exchange  rates in effect during the year.  The
cumulative  effect  resulting from such translation is recorded as remeasurement
gain or loss in the financial statements.


LOSS PER SHARE
--------------

Basic loss per share is computed on the basis of the weighted  average number of
common shares  outstanding  during each year. Diluted loss per share is computed
on the  basis of the  weighted  average  number of common  shares  and  dilutive
securities  outstanding.  Dilutive  securities having an antidilutive  effect on
diluted loss per share are excluded from the calculation.


                                       7
<PAGE>


                                 DURAVEST, INC.

                          NOTES TO FINANCIAL STATEMENTS



1.   GOING CONCERN
     -------------

     The  accompanying  financial  statements  were  prepared  assuming that the
     Company  will  continue  as a  going  concern.  This  basis  of  accounting
     contemplates  the  realization  of  assets  and  the  satisfaction  of  its
     liabilities in the normal course of operations. Since inception the Company
     has  incurred  losses of  approximately  $4 million  and has not  reached a
     profitable level of operations,  all of which raise substantial doubt about
     the Company's ability to continue as a going concern.

     The Company's  continued existence is dependent upon its ability to resolve
     its liquidity problems,  principally by obtaining additional debt financing
     and equity capital.  While pursuing additional debt and equity funding, the
     Company must continue to operate on limited cash flow generated internally.

     The  financial  statements  do not include any  adjustments  to reflect the
     possible future effects on the  recoverability and classification of assets
     or the amounts and  classification  of liabilities that may result from the
     possible inability of the Company to continue as a going concern.

     Accordingly, there are no assurances that the Company will be successful in
     achieving the above plans, or that such plans, if consummated,  will enable
     the Company to obtain profitable operations or continue as a going concern.


2.   COMMON STOCK
     ------------

     In November,  2001 the Board of Directors  authorized a stock split so that
     each one share of common stock outstanding became tn shares of common stock
     outstanding.   Prior  to  the  split  80,000,000  shares  were  authorized,
     3,676,664  common  shares were issued and  outstanding.  Subsequent  to the
     stock split 80,000,000  common shares were authorized and 36,766,640 shares
     were issued and outstanding.  All share and per share information  included
     in the  financial  statements  and the related  notes has been  restated to
     reflect the stock split

     The following reconciles the components of the loss per share computation:



                                       8
<PAGE>

                                 DURAVEST, INC.

                          NOTES TO FINANCIAL STATEMENTS

<TABLE>
<CAPTION>

      For the nine months ended
      September 30,                             2002                                   2001
                               -------------------------------------   -------------------------------------
                                  Income       Shares      Per-Share     Income        Shares      Per-Share
                               (Numerator)  (Denominator)    Amount    (Numerator)  (Denominator)    Amount
                               -----------  -------------  ---------   -----------  -------------  ---------
     <S>                        <C>           <C>            <C>        <C>           <C>            <C>
     Loss per common share

         Net (loss)
         available to
         common
         shareholders           $(28,002)     36,766,64     $ (0.01)    $(43,414)     36,766,640    $ (0.01)
                                --------      ---------     -------     --------      ----------    -------
         Net (loss)
         available
         to  common
         shareholders
         plus assumed
         conversions            $(28,002)     36,766,64     $ (0.01)    $(43,414)     36,766,640    $ (0.01)
                                ========      =========     =======     ========      ==========    =======
</TABLE>

3.   INCOME TAXES
     ------------

     Deferred income taxes reflect the net tax effects of temporary  differences
     between  the  carrying  amounts of assets  and  liabilities  for  financial
     reporting  purposes  and the  amounts  used for  income  tax  purposes.  At
     December 31, 2001,  the Company had federal net  operating  losses (NOL) of
     approximately  $439,657. The NOL expires in the years 2018 through 2021. In
     the event that a change in  ownership  of the  Company  of greater  than 50
     percent occurs/occurred as a result of the Company's issuance of common and
     preferred stock, the utilization of the NOL carryforward will be subject to
     limitation under certain provisions of the Internal Revenue Code.

     Realization of any portion of the  approximate $ 159,480  deferred  federal
     tax asset at September 30, 2002 is not  considered  more likely than not by
     management;  accordingly, a valuation of allowance has been established for
     the full amount of such asset.

     The  reconciliation  of income tax benefit  computed  at the United  States
     federal tax rate of 34% to income tax benefit is as follows:

      Nine months ended Sep. 30,                  2002              2001
      --------------------------               ----------        -----------

      Tax benefit at the United States
      statutory rate                           $    9,521        $   14,761
      State income tax benefit, net                   476               738
      Valuation allowance adjustment
                                                   (9,997)          (15,499)
                                               ----------        ----------

      Income tax benefit                       $        -        $        -
                                               ==========        ==========



                                       9
<PAGE>


                                 DURAVEST, INC.

                          NOTES TO FINANCIAL STATEMENTS


     Significant components of the Company's deferred tax assets and liabilities
     are as follows:


     September 30,                                2002              2001
     -------------                             ----------        ----------

     Deferred tax assets:
         Net operating loss
     carryforwards                             $ 159,480         $ 142,137
     Valuation allowance for deferred
         tax assets                             (159,480)         (142,137)
                                               ---------         ---------
     Net deferred tax asset                    $       -         $       -
                                               =========         =========


4.   RELATED PARTY TRANSACTIONS CONSULTING SERVICES
     ----------------------------------------------

     The Company  neither owns or leases any real  property.  Fees totaling $629
     and $500 have been paid to officers  and  companies  owned by  shareholders
     during the periods  ended  September  30, 2002 and 2001 for  administrative
     fees,  consulting  services  rendered  and,  expenses paid on behalf of the
     Company.  The officers  and  directors of the Company are involved in other
     business  activities  and may,  in the  future,  become  involved  in other
     business opportunities.


5.   COMMITMENT AND CONTINGENCIES
     ----------------------------

     The Company conducts its operations from leased facilities, under operating
     leases on a month-to-month  basis,  which can be terminated by either party
     upon giving notice 30 days in advance.

     Lease rent  expense  for the  periods  ended  September  30,  2002 and 2001
     amounted  to $814 and $0. At  September  30,  2002,  future  minimum  lease
     payments and rent usage tax were $0.

6.   SUPPLEMENTAL CASH FLOW INFORMATION
     ----------------------------------

     Supplemental disclosure is as follows:


     September 30,                          2002              2001
     -------------                        --------          --------

     Cash paid for interest               $      -          $      -
     Cash paid for taxes                         -                 -


8.   CONDITIONAL ACQUISITION AGREEMENT
     ---------------------------------

     On April 4, 2002 th  Company  entered  into a  conditional  stock  exchange
     agreement with Cardio  Management  Systems,  Inc.("Cardio"),  a corporation
     organized under the Canadian Business Corporation Act. Under the agreement,
     if certain  conditions are met, the Company will issue 5,000,000  shares of
     its common stock in exchange for 1,000,000  shares of Cardio stock and as a
     result Cardio will become a wholly owned  subsidiary.  The principal assets



                                       10
<PAGE>


                                 DURAVEST, INC.

                          NOTES TO FINANCIAL STATEMENTS


     of Cardio are shares of common stock of Estracure,  Inc.  ("Estracure"),  a
     corporation  organized under the Canadian  Business  Corporation Act and an
     optional right to acquire  additional  shares of Estracure common stock, at
     no time to exceed 50% ownership of Estracure  outstanding  common stock. If
     the stock  exchange is  completed  the stock of  Estracure  owned by Cardio
     could be considered to be  "investment  securities"  as such are defined by
     the Investment  Company Act of 1940 ("40 Act"). The condition  precedent to
     the completion of the stock exchange shall be the receipt by Duravest, Inc.
     of either (1) a "no-action"  letter from the SEC that the completion of the
     stock  exchange  with the resultant  ownership by Duravest,  Inc. of Cardio
     with its  investment  in Estracure  (with  Estracure  not being a "majority
     owned subsidiary" of Cardio under the 40 Act) will not cause a violation of
     the 40 Act; or (2) an opinion of counsel that the  completion  of the stock
     exchange with the resultant ownership by Duravest,  inc. of Cardio with its
     investment  in  Estracure  (with  Estracure  not  being a  "majority  owned
     subsidiary"  of Cardio  under the 40 Act) will not cause a violation of the
     40 Act. Duravest, Inc. intends to pursue the satisfaction of either or both
     of these two  conditions.  However,  there is no assurance  that it will be
     able to satisfy either of them.







                                       11


<PAGE>


ITEM 2. PLAN OF OPERATION
-------------------------

     DuraVest,  Inc. (the "Issuer" or  "DuraVest")  is continuing its efforts to
find a new business opportunity.  The Issuer will seek and attempt to enter into
a business  combination of acquisition or assets by which it will become engaged
in an active business venture. It is likely that, if such a transaction is made,
it will involve  control of the Issuer being  acquired by the other party to the
transaction.

     On April 4, 2002 the  Issuer  entered  into a  Conditional  Stock  Exchange
Agreement  ("Exchange  Agreement")  with  Cardio  Management  Systems,  Inc.,  a
corporation organized under the Canada Business Corporation Act ("Cardio"),  and
Ms. Patti Cooke,  the sole record  stockholder  of Cardio.  (Ms. Cooke holds the
Cardio shares as a nominee for undisclosed principals. She is also the President
and a director  of the  Issuer.)  Under the  Exchange  Agreement,  if  specified
conditions  are met,  the Issuer will  acquire all of the  outstanding  stock of
Cardio in exchange  for  5,000,000  shares of the  Issuer's  common  stock.  The
Issuer's stock would be issued as  "restricted  securities " as such are defined
under the  Securities  Act of 1933.  They would be issued in  reliance  upon the
exemption from registration under Section 5 of that Act provided in Section 4(2)
thereof or Regulation D adopted thereunder.

     Cardio was recently formed to provide funds to and acquire an investment in
Estracure, Inc., a Canadian corporation (Estracure").  Cardio has acquired 26 of
the 100 shares of Estracure  presently  outstanding for which it paid $2,500,000
(Canadian - which  equated to $1,590,000  U.S. as of May 8, 2002).  Estracure is
involved  in the  research,  development  and  commercialization  of the  use of
"Estradiol" to reduce restenosis after  angioplasty (see additional  description
following).  If the  undergoing  human  clinical  trails of Estradiol are deemed
successful,  Cardio has the option to acquire  sufficient  additional  shares of
Estracure  to bring  its  ownership  interest  therein  to 50% in  exchange  for
$7,500,000 Canadian ($4,785,600 U.S. as of September 5, 2002).

     The  contractual  arrangements  between  Cardio and Estracure  provide that
Cardio may not, at any time,  acquire  more than 50% of the  outstanding  common
stock of  Estracure  (which  prohibition  is  designed to protect  valuable  and
favorable  Canadian  Tax  treatment  for  Estracure  and its  shareholders).  If
DuraVest  acquires the stock of Cardio it could be considered to be  "investment
securities"  as such are defined under the  Investment  Company Act of 1940 ("40
Act") and their  ownership  by Cardio as a wholly owned  subsidiary  of DuraVest
could cause DuraVest to become an unregistered  inadvertent  investment  company
under the 40 Act. The parties to the Exchange  Agreement  have been advised that
the circumstances of the Cardio investment in Estracure are such that there is a
reasonable  possibility  that:  (i)  DuraVest  could  apply  for  and  obtain  a
"no-action"  letter from the United States  Securities  and Exchange  Commission
("SEC") under which the Cardio  acquisition could be completed without causing a
violation  of  the 40 Act  by  DuraVest;  or  (ii)  if  DuraVest  would  acquire
sufficient additional assets so that the Estracure investment would be less than
40% of its total  assets less cash items,  DuraVest  could  obtain an opinion of
counsel  that  the  completion  of the  Cardio  acquisition  would  not  cause a
violation of the 40 Act by DuraVest.

     Accordingly,  the  completion of the  acquisition  of Cardio by DuraVest is
conditioned upon the receipt of DuraVest of either:

     (i)  A  "no-action"  letter from the SEC that the  completion of the Cardio
          acquisition  with the  resultant  ownership by DuraVest of Cardio with
          its  investment  in Estracure  (with  Estracure  now being a "majority
          owned  subsidiary"  of  Cardio  under  the 40 Act)  will  not  cause a
          violation of the 40 Act; or

     (ii) an opinion of counsel that the  completion  of the Cardio  acquisition
          with the resultant ownership by DuraVest of Cardio with its investment
          in Estracure (with  Estracure not being a "majority owned  subsidiary"
          of Cardio under the 40 Act) will not cause a violation of the 40 Act.




                                       12
<PAGE>


DuraVest  intends  to  pursue  the  satisfaction  of either or both of these two
conditions  or to amend the  Cardio-Estracure  arrangements  to enable Cardio to
acquire more than 50% of Estracure.  However, there is no assurance,  it will be
able  to   satisfy   either   of  the  state   requirements   or  to  amend  the
Cardio-Estracure arrangements.

     The only material  assets of Cardio are its investment in Estracure and its
option to acquire  additional  stock in  Estracure.  Neither  Cardio or DuraVest
presently have the funds to finance the exercise of Cardio's  options to acquire
additional Estracure stock.  Accordingly,  their ability to exercise this option
will be dependent upon their ability to raise  additional  capital.  There is no
assurance  that:  (i)  Estracure's   human  clinical  trials  of  the  Estradiol
treatments  will be  successful;  (ii) Cardio or DuraVest  will be able to raise
sufficient  capital to exercise the option to acquire the  additional  Estracure
stock; or (iii) Estracure will be able to successfully  develop and commercially
market Estradiol.

     The  shareholders  of  Estracure,  including  Cardio,  have  entered into a
"Shareholders Agreement", the principal provisions of which are as follows:

     (i)  Cardio is entitled to nominate two of the five members of the Board of
          Directors;

    (ii)  Subject to the option of Cardio to subscribe to  additional  shares in
          consideration of the sum of C$7,500,000, the shareholders of Estracure
          benefit from a preemptive right to subscribe,  on a pro rata basis, to
          any additional shares issued to Estracure;

   (iii)  A Shareholder  of Estracure may only assign its shares  therein in the
          following circumstances:

          -    The  assignment is made to an affiliate,  subsidiary,  or holding
               company of said shareholder,  provided,  where such a shareholder
               is Cardio and the assignee is DuraVest,  that as a result of such
               assignment,  DuraVest  must not be  considered to have control of
               Estracure  nor,  in  the  opinion  of  Estracure,  may  it  be in
               violation of the Investment Company Act of 1940 (US); or

          -    such  a   shareholder   has  offered  his  shares  to  the  other
               shareholders  who are  entitled  to  acquire  same on a pro  rata
               basis.

    (iv)  In the event that one or more shareholders  holding, in the aggregate,
          more than 50% of the issued and outstanding  shares of Estracure which
          to assign their shares to a third party,  the  remaining  shareholders
          may  require  that  their  shares be  purchased  on the same terms and
          conditions.  Inversely, under the same circumstances, the shareholders
          controlling  more than 50% of the  issued  and  outstanding  shares of
          Estracure  may compel  the  remaining  shareholders  to sell to such a
          third party.

     (v)  A  Shareholder  shall be deemed to sell all of its shares in Estracure
          upon the  occurrence  of certain  events,  the  following of which are
          applicable to Cardio:

          -    change  of  control  of  Cardio  except  for its  Acquisition  by
               DuraVest without the unanimous consent of the other  shareholders
               of Estracure;

          -    the  seizure  of a  shareholder's  shares in  Estracure  and such
               seizure is not or contested within 30 days thereof;

          -    the bankruptcy of a shareholder;

          -    fraud by a shareholder;

          -    criminal Act by a shareholder;

          -    the  default  of  a  shareholder  in  respecting  anyone  of  its
               obligation  under the  terms of  Shareholders  Agreement  in such
               default has not been remedied within a reasonable time; and




                                       13
<PAGE>



    (vi)  Decisions  in respect of a number of matters have been made subject to
          the  consent  of the  shareholders,  either  by a 75%  majority  or by
          unanimous approval.

     Estracure's  Estradiol  project  has been  developed  by a team of Canadian
medical  researchers working under the auspices of the Montreal Heart Institute.
They began their  research in 1997 to determine why  arteriosclerosis  and other
diseases  creating  induration of the arteries  occurred more  frequently in men
than women.  They  focused  their  efforts on the  potential  role of  naturally
occurring hormones unique to women in blocking the onset of  arteriosclerosis or
other induration of the arteries.  After  preliminary  trials they focused their
efforts on a form of Estradiol (17-beta Estradiol),  a female sex hormone of the
estrogen family. At this point their goal was to develop a product and treatment
which  would  reduce  the  recurrence  of  blockage   following  an  angioplasty
procedure, a non-surgical  interventional procedure using a tiny balloon to open
blocked  arterial  passages and the use of intravascular  stents.  The Estracure
treatment  involves  the  application  or  injection  of  Estradiol  during  the
angioplasty procedure to impede the re-blocking of the arterial passage.

     The  results  of the  research  to date have been  promising.  The  initial
theoretical  studies have been  followed by work in a more  clinically  relevant
model,  the stent  porcine  coronary  artery  model,  where  there was a renewed
confirmation of restenosis as well as a lower inflammatory score.

     Estracure is now proceeding to set up human  clinical  trials of Estradiol.
Estacure has received  approval from  Canadian  health  authorities  to initiate
Phase II clinical  trail of  17-B-Estradiol  in the  prevention of restenosis in
patients following  percutaneous  transluminal  coronary  angioplasty (PTCA) and
stent implantation.

     The Phase II clinical trial which has just started will evaluate the safety
and efficacy of  17-B-Estradiol  in patients  narrowing or  constricting  of the
coronary  arteries caused by  atheroscierotic  disease.  17-B-Estradiol  will be
locally  administered in minimally  invasive  fashion by bolus infusion during a
PTCA procedure.  Contrary to other  anti-restenosis  drugs presently in clinical
evaluation,  17-B-Estradiol is a non-toxic  naturally  occuring hormone that has
been shown by Estracure's  scientific team to have a dual  beneficial  effect in
improving vascular healing and preventing  restenosis after angioplasty.  Animal
studies have demonstrated  that local delivery of  17-B-Estradiol  significantly
decreases neointimal hyperplasia after PTCA without secondary effects.

     If the  results of these  trials  are  satisfactory,  Estracure  intends to
proceed with the research and  development  of Estradiol  and take the necessary
actions to make it,  including  obtaining  the necessary  regulatory  approvals.
Before Estracure can proceed beyond the human clinical  trials,  it will have to
acquire  additional  funding.  If  Cardio  is not  able to  provide  capital  by
exercising its option, Estracure will have to pursue other sources not now known
to it.

     Except for the arrangements with Cardio,  there are no present arrangements
for, or ongoing  negotiations with respect to, all business combination with the
Issuer.  The Issuer has no present knowledge of any other specific candidate for
a business  combination.  The  management  of DuraVest  believes it will have to
acquire  additional  capital to continue its operations over the next 12 months.
If it acquires  Cardio during that period and desires for Cardio to exercise its
option to purchase additional Estracure stock,  DuraVest will have to obtain the
C$7,500,000   necessary  for  the  option  and  additional  capital  to  finance
DuraVest's operations.  There are no present arrangements for the acquisition of
any additional capital or any assurance that such will be available.

     The Issuer has entered into a written  agreement  under which the equipment
manufacturer with whom the Issuer had made a $100,000 advance deposit has agreed
to return the deposit in five monthly  installments  of $20,000 of the first day
of each month  commencing  May 1, 2000.  The Issuer  received  two  payments  of
$20,000 each under the settlement  agreement.  The manufacturer has indicated it
is unable or unwilling to complete the payments. The Issuer is in the process of
pursuing collection proceedings against the other party.


                                       14
<PAGE>


                           PART II - OTHER INFORMATION


Item 1.   Legal Proceedings

          Not Applicable


Item 2.   Changes in Securities

          Not Applicable


Item 3.   Defaults in Senior Securities

          Not Applicable


Item 4.   Submission of Matters to a Vote of Securities Holders

          Not Applicable

Item 5.   Other Information

          Not Applicable


Item 6.   Exhibit and Reports on Form 8-K

          (a)      Exhibits:

                   99.1   Certification Pursuant to Section 906 of the Sarbanes-
                          Oxley Act

          (b)      Form 8-Ks:

                   No  Reports of Form 8-K were  filed  during  the  three-month
period ended September 30, 2002.




                                       15
<PAGE>

                                   SIGNATURES
                                   ----------

In  accordance  with the Exchange Act, the  registrant  caused this report to be
signed on its behalf by the undersigned, thereunto duly authorized.

                                   DURAVEST, INC.

Dated: November 8, 2002            By: /s/ Patti Cooke
                                       -----------------------------------------
                                       Patti Cooke, President and Principal
                                       Executive, and Accounting Officer
                                       and Director

Dated: November 8, 2002            By: /s/ Bradley R. Wilson
                                       -----------------------------------------
                                       Bradley R. Wilson, Vice President and
                                       Principal Financial Officer and Director










                                       16

<PAGE>
                                 CERTIFICATIONS

I, Patti Cooke, certify that:

1.   I have reviewed this quarterly report on Form 10-QSB of DuraVest, Inc.;

2.   Based on my knowledge,  this  quarterly  report does not contain any untrue
     statement of a material fact or omit to state a material fact  necessary to
     make the statements  made, in light of the  circumstances  under which such
     statements  were made, not misleading with respect to the period covered by
     this quarterly report;

3.   Based on my  knowledge,  the  financial  statements,  and  other  financial
     information  included  in this  quarterly  report,  fairly  present  in all
     material respects the financial  condition,  results of operations and cash
     flows of the  registrant  as of, and for,  the  periods  presented  in this
     quarterly report;

4.   The  registrant's  other  certifying  officers  and I are  responsible  for
     establishing and maintaining disclosure controls and procedures (as defined
     in Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:

a)   designed such  disclosure  controls and  procedures to ensure that material
     information   relating  to  the  registrant,   including  its  consolidated
     subsidiaries,  is  made  known  to  us by  others  within  those  entities,
     particularly  during  the period in which  this  quarterly  report is being
     prepared;

b)   evaluated the  effectiveness  of the registrant's  disclosure  controls and
     procedures  as of a date  within 90 days prior to the  filing  date of this
     quarterly date (the "Evaluation Date"); and

c)   presented in this quarterly report our conclusions  about the effectiveness
     of the disclosure controls and procedures based on our evaluation as of the
     Evaluation Date;

5.   The registrant's other certifying  officers and I have disclosed,  based on
     our most recent  evaluation,  to the  registrant's  auditors  and the audit
     committee of  registrant's  board of directors  (or person  performing  the
     equivalent functions):

a)   all  significant  deficiencies  in the  design  or  operation  of  internal
     controls which could adversely affect the  registrant's  ability to record,
     process,  summarize and report  financial data and have  identified for the
     registrant's auditors any material weaknesses in internal controls; and

b)   any fraud,  whether or not  material,  that  involves  management  or other
     employees  who  have  a  significant  role  in  the  registrant's  internal
     controls; and

6.   The  registrant's  other  certifying  officers and I have indicated in this
     quarterly report whether or not there were significant  changes in internal
     controls  or in other  factors  that could  significantly  affect  internal
     controls  subsequent to the date of our most recent  evaluation,  including
     any corrective actions with regard to significant deficiencies and material
     weaknesses.

      Date: November 11, 2002              /s/ Patti Cooke
                                           -------------------------------------
                                           Patti Cooke
                                           President and Principal Executive
                                           Financial and Accounting Officer



                                       17